---
title: "Oncology Clinical Research Feed | MedicHelpline"
specialty: "Oncology"
specialty_slug: "oncology"
canonical_url: "https://medichelpline.com/clinical-feed/oncology"
content_type: "clinical_feed_specialty"
page: 1
articles_in_batch: 30
generated_at: "2026-09-05T23:52:18.866Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Oncology — Clinical Research Feed
## Specialty Overview: Oncology
Latest peer-reviewed clinical trials, guidelines, and observational research in **Oncology**, indexed and structured for clinical intelligence and AI reasoning.
## Latest Oncology Publications
### 1. [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-05
- **Detail Markdown URL:** [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)

> **Executive GIST:** - This retrospective diagnostic model-development and internal validation study used 1,199 histopathology-verified dermoscopic images (578 benign, 621 malignant) drawn from an initial ISIC Archive screen of 552,869 records. - The authors developed an ensemble that fuses ImageNet-pretrained **EfficientNetB0** and **Swin-T (Swin Transformer Tiny)** features to classify lesions as benign melanocytic lesions or malignant **melanoma**. - Patient-independent five-fold validation was performed with weighted sampling, mixup, label smoothing, AdamW optimization, early stopping, and five-view test-time augmentation to reduce overfitting and data leakage. - Reported mean performance: accuracy 0.89325 ± 0.03179, ROC-AUC 0.96348 ± 0.01695, and support-weighted F1-score 0.89300 ± 0.03220. Fold-level 95% CIs: accuracy 0.8538–0.9327, ROC-AUC 0.9424–0.9845. - Pooled confusion counts: 526 true negatives, 52 false positives, 76 false negatives, 545 true positives; sensitivity 87.76% and specificity 91.00% were calculated from these pooled counts. - Explainability checks used qualitative **Grad-CAM** review; peripheral artifact activation was observed in two false positives and lesion-centered activation in two true positives, but interpretability findings were not scored systematically. - Limitations explicitly reported: use of validation folds for early stopping/checkpoint selection, absence of device-stratified analysis, no systematic interpretability scoring, no calibration assessment, and lack of independent external validation. - Data availability: source images and metadata are public via the ISIC Archive; the filtered 1,199-image cohort manifest and metadata are available from the corresponding author on reasonable request and per ISIC terms. - Authors emphasize the ensemble is intended only as a clinician-facing adjunct and that external validation is required before clinical use or claims of generalizability.

### 2. [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)
- **Source:** British Journal of Cancer | **Published:** 2026-09-05
- **Detail Markdown URL:** [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)

> **Executive GIST:** - The study evaluated whether peripheral **receptor occupancy** is an appropriate dosing surrogate for the PD‑1 inhibitor **pembrolizumab** in non‑small cell lung cancer. - A physiological pharmacokinetic model was built to describe plasma and intratumoural pembrolizumab kinetics and was extended to include receptor occupancy and ex vivo–derived interleukin‑2 (IL‑2) induction parameters. - Simulations compared three approved pembrolizumab regimens: 2 mg/kg every 3 weeks (Q3W), 200 mg Q3W, and 400 mg every 6 weeks (Q6W). - All simulated regimens produced near‑complete PD‑1 receptor occupancy in both plasma and tumour compartments, replicating the clinical rationale for current dosing strategies. - Despite sustained receptor occupancy, predicted **IL‑2** concentrations varied across the dosing interval and tracked pembrolizumab concentration rather than receptor occupancy, indicating dynamic pharmacodynamic effects. - The 400 mg Q6W regimen produced the highest predicted IL‑2 levels; intratumoural IL‑2 changes were smaller than plasma changes. - Authors conclude that receptor occupancy did not predict immune activation in the model and therefore may be an inadequate pharmacodynamic surrogate for pembrolizumab dose selection. - The findings challenge receptor‑occupancy‑driven dosing approaches for PD‑1 inhibitors and highlight the need for robust pharmacodynamic markers and clearer definitions of the immune activation required for efficacy. - All study data are available on reasonable request; the article includes model figures and cites prior work on dosing strategies and ex vivo pharmacology revealing dissociation between receptor occupancy and T cell function.

### 3. [MIR100HG drives HCC tumorigenic traits via p38/MAPK and AKT signaling in an oxygen-dependent manner](https://medichelpline.com/clinical-feed/pubmed-42698010.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1007/s10142-026-02033-5](https://doi.org/10.1007%2Fs10142-026-02033-5)
- **Detail Markdown URL:** [MIR100HG drives HCC tumorigenic traits via p38/MAPK and AKT signaling in an oxygen-dependent manner](https://medichelpline.com/clinical-feed/pubmed-42698010.md)

> **Executive GIST:** - Hepatocellular carcinoma (HCC) progression is promoted by hypoxic tumor microenvironments that alter signaling and therapeutic responses. - The long non-coding RNA **MIR100HG** was evaluated for expression and function in epithelial-like Hep3B and mesenchymal-like SNU-398 HCC cell lines and in non-tumor Clone-9 hepatocytes. - Gain- and loss-of-function experiments (overexpression and silencing) were used to assess effects on proliferation, clonogenicity, migration, invasion, and apoptosis under both normoxic and hypoxia-mimicking conditions. - **MIR100HG overexpression** increased cell proliferation, colony formation, migration, and invasion; **MIR100HG silencing** suppressed these tumorigenic phenotypes and increased apoptotic cell death. - Mechanistically, MIR100HG promoted oncogenic signaling through activation (phosphorylation) of **p38/MAPK** and **AKT** under normoxic conditions; MIR100HG depletion reduced phosphorylation of these proteins. - Under hypoxia-mimicking conditions, the MIR100HG-associated activation of p38/MAPK and AKT observed in normoxia was not preserved, indicating a context-dependent signaling response. - Expression of AKT-associated regulatory genes such as **GAS6** and **PTEN** was reversed under hypoxia-mimicking conditions compared with normoxia, reflecting hypoxia-driven remodeling of downstream pathways. - The study identifies MIR100HG as a **hypoxia-associated oncogenic regulator** in HCC, supporting its potential as a biomarker and therapeutic target; details on in vivo validation and clinical correlation were not reported in the source abstract. - The authors declared no competing interests and stated that ethical approval was not required because no animal or human subjects were used.

### 4. [Efficient TD-DFT Protocols for UV-Vis Spectra of Pt(II) Luminescent Probes in Cancer Detection](https://medichelpline.com/clinical-feed/pubmed-42609127.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1002/jcc.70481](https://doi.org/10.1002%2Fjcc.70481)
- **Detail Markdown URL:** [Efficient TD-DFT Protocols for UV-Vis Spectra of Pt(II) Luminescent Probes in Cancer Detection](https://medichelpline.com/clinical-feed/pubmed-42609127.md)

> **Executive GIST:** - Luminescent transition metal complexes, particularly **Pt(II)** pincer complexes, are promising biomolecular probes because their photophysical properties change with environment, enabling detection of DNA-associated abnormalities relevant to cancer. - Computational prediction of optical properties is essential for screening candidate probes, but reliable protocols for transition metal intercalators are limited. - This study benchmarks methods for UV-Vis absorption spectra of a Pt(II) pincer complex both isolated and intercalated in a small DNA model. - Approximations that accelerate calculations were evaluated: the **Tamm–Dancoff approximation (TDA)** and the **resolution of identity (RI)** significantly speed up TD-DFT with modest accuracy loss. - Geometry optimization dominates computational cost; **PBEh-3c** is proposed as an efficient alternative to conventional DFT with errors comparable to those from TDA. - Tight-binding methods (GFN-xTB variants) further reduce cost but introduce larger deviations in optimized structures and UV-Vis spectra, limiting their reliability unless extensive optimization is required. - The exchange-correlation functional used in TD-DFT is the largest source of uncertainty; **PBE0** on PBEh-3c geometries provided good results in this benchmark. - Spin–orbit coupling (SOC), basis set choices, and range-separated functionals were examined across figures; overall, balancing accuracy and efficiency depends on objective (screening vs. high-accuracy prediction). - Authors declare no conflicts of interest.

### 5. [Hydrogel strategies to remodel the tumor microenvironment for improved cancer immunotherapy](https://medichelpline.com/clinical-feed/pubmed-42562132.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127286](https://doi.org/10.1016%2Fj.ijpharm.2026.127286)
- **Detail Markdown URL:** [Hydrogel strategies to remodel the tumor microenvironment for improved cancer immunotherapy](https://medichelpline.com/clinical-feed/pubmed-42562132.md)

> **Executive GIST:** - Cancer remains a leading cause of death worldwide and existing therapies (chemotherapy, surgery, radiotherapy, immunotherapy) are limited by an antagonistic **tumor microenvironment** (TME). - Drug delivery systems at nano-, micro-, and macro-scales can remodel the TME by improving pharmacokinetics and coordinating multiple therapeutic modalities. - **Hydrogels** are particularly promising for TME modulation because of their **tunable microstructures**, high drug loading capacity, and scalable manufacturing. - Recent work has focused on hydrogel-based, drug-loaded platforms to modulate the TME specifically for **tumor immunotherapy**. - Strategies target conversion of immunologically distinct tumor phenotypes: **hot tumors** (inflamed), **cold tumors** (non-inflamed), including **immune-desert** and **immune-excluded** phenotypes. - Remodeling approaches aim to enhance immune infiltration, overcome immune suppression, and coordinate local delivery of agents to improve efficacy and safety. - The review summarizes underlying immunological mechanisms by which hydrogels modulate the TME, including effects on immune cell recruitment and local pharmacokinetics. - Key translational challenges remain for hydrogel-based TME modulation, such as clinical translation barriers, manufacturing, safety, and integration with current therapies. - The authors highlight the potential of hydrogels to provide coordinated, local, and sustained modulation of the TME to augment anti-tumor treatments and immunotherapies.

### 6. [Magnetic Nanoparticles for Cancer Imaging and Theranostics: SPION and USPION Advances](https://medichelpline.com/clinical-feed/pubmed-42551722.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127261](https://doi.org/10.1016%2Fj.ijpharm.2026.127261)
- **Detail Markdown URL:** [Magnetic Nanoparticles for Cancer Imaging and Theranostics: SPION and USPION Advances](https://medichelpline.com/clinical-feed/pubmed-42551722.md)

> **Executive GIST:** - Cancer treatment is limited by poor specificity of chemotherapeutic and imaging agents, causing reduced efficacy and high systemic toxicity. - **Magnetic nanoparticles (MNPs)**, notably **Superparamagnetic Iron Oxide Nanoparticles (SPION)** and **Ultrasmall SPION (USPION)**, offer theranostic potential due to magnetic responsiveness and biocompatibility. - Iron oxide materials such as **Fe3O4 (magnetite)** and maghemite (γ-Fe2O3) can integrate imaging, targeting, hyperthermia, and drug delivery in a single platform. - Recent progress covers synthesis methods, surface modification with biocompatible polymers and targeting ligands, and physicochemical characterization to optimize biological performance. - Targeting and controlled delivery strategies highlighted include magnetic field–guided localization, stimuli-responsive drug release, ligand-mediated targeting, and multifunctional nanocarrier design. - Advances in **magnetic resonance imaging (MRI)**, image-guided therapy, multimodal therapy, and clinically relevant theranostic applications are summarized and critically discussed. - Translation challenges remain significant: scale-up, long-term safety, regulatory hurdles, and clinical translation pathways were identified as current obstacles. - Authors conclude that SPION- and USPION-based magnetic nanoplatforms are a promising route to precision oncology by combining diagnostic, therapeutic, and monitoring functions in one nanoplatform to support personalized cancer treatment.

### 7. [Vorinostat-loaded PLGA-PEG-AEAA Nanocarrier Enhances Targeted Therapy for Colorectal Cancer](https://medichelpline.com/clinical-feed/pubmed-42546991.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127274](https://doi.org/10.1016%2Fj.ijpharm.2026.127274)
- **Detail Markdown URL:** [Vorinostat-loaded PLGA-PEG-AEAA Nanocarrier Enhances Targeted Therapy for Colorectal Cancer](https://medichelpline.com/clinical-feed/pubmed-42546991.md)

> **Executive GIST:** - Colorectal cancer (CRC) is a leading cause of cancer death worldwide; Histone deacetylase (HDAC) inhibitors such as **vorinostat** induce cell cycle arrest and apoptosis and are promising anticancer agents. - Clinical use of vorinostat in solid tumors is limited by rapid systemic clearance, poor tumor distribution, and off-target delivery. - The authors developed a targeted nanoformulation (T-NP.VOR) based on a **PLGA-PEG-AEAA** carrier; AEAA (aminoethyl anisamide) is used for targeting. - In vitro, T-NP.VOR increased cellular uptake by CRC cells via **Sigma‑1 receptor**-mediated internalization, producing enhanced HDAC inhibition, cell cycle blockade, and apoptosis compared with free drug or non-targeted nanoparticles. - In an orthotopic CRC mouse model, T-NP.VOR prolonged blood circulation and improved tumor distribution relative to free vorinostat and a non-targeted nanoformulation. - Improved pharmacokinetics and tumor delivery of T-NP.VOR translated into significant tumor growth suppression and extended survival in treated animals. - The study supports the **PLGA-PEG-AEAA** nanocarrier as a promising platform for targeted delivery of vorinostat in CRC therapy. - Specific experimental details (e.g., exact dosing, quantitative uptake metrics, statistical values) and full methodological parameters were not reported in the PubMed abstract and require consultation of the full text for confirmation.

### 8. [ZIF-90-PQ Cascade Nanoplatform (CP@ZIF-PQ/Ce6) for Multimodal Breast Cancer Therapy](https://medichelpline.com/clinical-feed/pubmed-42532321.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127255](https://doi.org/10.1016%2Fj.ijpharm.2026.127255)
- **Detail Markdown URL:** [ZIF-90-PQ Cascade Nanoplatform (CP@ZIF-PQ/Ce6) for Multimodal Breast Cancer Therapy](https://medichelpline.com/clinical-feed/pubmed-42532321.md)

> **Executive GIST:** - The study reports a **ZIF-90-based multimodal nanosystem** named CP@ZIF-PQ/Ce6 NPs designed for breast cancer treatment, combining multiple therapeutic modalities to overcome tumor microenvironment limitations. - The nanosystem is loaded with **copper peroxide (CP)** nanoparticles, the autophagy inhibitor **primaquine phosphate (PQ)**, and the photosensitizer **Ce6** to integrate photodynamic therapy (PDT), chemodynamic therapy (CDT), oxygen generation, and autophagy inhibition. - The combined PDT/CDT/O2-generation/autophagy-inhibition strategy is intended to increase **reactive oxygen species (ROS)** production, relieve tumor hypoxia, and prevent autophagy-mediated tumor cell protection. - CP@ZIF-PQ/Ce6 NPs exhibit **dual pH- and ATP-responsive** behavior, enabling triggered drug release within the tumor microenvironment. - The authors report potent antitumor activity and favorable biocompatibility of the nanosystem in both in vitro and in vivo models, demonstrating feasibility of multimodal cooperative therapy. - The work positions multimodal, tumor-microenvironment–responsive nanosystems as a promising strategy to address the intrinsic limitations of monotherapy in solid tumors such as breast cancer. - Keywords emphasized in the study include **antitumor**, **autophagy inhibition therapy**, **chemodynamic and photodynamic therapy**, **multimodal therapy**, and **ZIF-90**.

### 9. [VEGF-A siRNA-loaded Nanocarriers for Anti‑angiogenic Cancer Therapy: Advances and Challenges](https://medichelpline.com/clinical-feed/pubmed-42521061.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127251](https://doi.org/10.1016%2Fj.ijpharm.2026.127251)
- **Detail Markdown URL:** [VEGF-A siRNA-loaded Nanocarriers for Anti‑angiogenic Cancer Therapy: Advances and Challenges](https://medichelpline.com/clinical-feed/pubmed-42521061.md)

> **Executive GIST:** - Angiogenesis is a core process in solid tumor progression and is primarily regulated by **VEGF‑A**, which promotes tumor vascularization, immune suppression, and therapeutic resistance. - Existing VEGF-targeting therapies (monoclonal antibodies, tyrosine kinase inhibitors) show clinical benefit but are limited by adaptive resistance, systemic toxicity, and incomplete VEGF signaling suppression. - **siRNA-mediated silencing of VEGF‑A (siVEGF‑A)** enables gene-specific inhibition at the mRNA level but faces delivery hurdles: rapid nuclease degradation, poor cellular uptake, and endosomal entrapment. - The review examines multiple **nanocarrier** platforms for siVEGF‑A delivery: lipid nanoparticles, polymeric and dendrimer carriers, inorganic platforms, biomimetic systems, and hybrid nanostructures. - Preclinical studies across cancer models report consistent VEGF knockdown, typically in the range of **60–80%**, with correlated reductions in tumor microvessel density and significant tumor growth inhibition. - Co‑delivery strategies that combine siVEGF‑A with chemotherapeutics (examples: **doxorubicin**, **irinotecan**) enhance antitumor efficacy by both suppressing angiogenesis and sensitizing tumors to cytotoxic agents. - Persistent translational barriers include formulation stability, biodistribution, immune activation, inefficient endosomal escape, and challenges in scalable manufacturing. - The review synthesizes mechanistic insights, therapeutic outcomes, and translational limitations to outline design principles and future directions for clinically translating VEGF‑A siRNA‑loaded nanocarriers.

### 10. [Anti-CD33 and polydopamine-coated curcumin‑ICG nanoparticles for in vitro leukemia cytotoxicity (s](https://medichelpline.com/clinical-feed/pubmed-42508510.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127202](https://doi.org/10.1016%2Fj.ijpharm.2026.127202)
- **Detail Markdown URL:** [Anti-CD33 and polydopamine-coated curcumin‑ICG nanoparticles for in vitro leukemia cytotoxicity (s](https://medichelpline.com/clinical-feed/pubmed-42508510.md)

> **Executive GIST:** - The PubMed record (PMID: **42508510**) describes an article titled “Multifunctional anti-CD33 antibody- and polydopamine-coated curcumin-indocyanine green nanoparticles for in vitro cytotoxic effects against leukemia cells.” - The article is published in International Journal of Pharmaceutics (Int J Pharm) and is listed as a free article. - DOI is 10.1016/j.ijpharm.2026.127202; electronic publication date is 2026 Jul 27; journal citation shows 2026 Sep 5:702:127202. - The lead and coauthors include Pinyadapat Aroonthongsawat, Xue Feng, Yuxuan Ji, Yuxiang Xue, Nurbanu Ozgultekin, Hongdi Wang, Mengguang Ye, Norbert Radacsi, Primana Punnakitikashem, Xianfeng Chen, and Yaneenart Suwanwong; multiple institutional affiliations are provided. - Affiliations span Chulalongkorn University (Thailand), University of Edinburgh (United Kingdom), Siriraj Hospital/Mahidol University (Thailand) and related centers; corresponding author electronic addresses are given for Xianfeng Chen and Yaneenart Suwanwong in the PubMed entry. - The title indicates the study developed **multifunctional nanoparticles** featuring an **anti-CD33 antibody** and **polydopamine** coating with curcumin and indocyanine green (ICG) payloads, intended to assess **in vitro cytotoxic effects against leukemia cells**. - The PubMed page does not include the article abstract text or experimental details in the provided content; specific methods, results, quantitative outcomes, statistical analyses, and conclusions are not reported in the visible source content. - The record links to Elsevier Science full-text options; however, the PubMed entry itself contains only bibliographic and affiliation metadata and not the study’s data or conclusions. - Users seeking experimental details, cytotoxicity outcomes, or translational implications will need to consult the full text via the publisher link or institutional access because those details are not present on the PubMed summary page supplied here.

### 11. [Directional coating of cell membranes preserves orientation and extends circulation of biomimetic](https://medichelpline.com/clinical-feed/pubmed-42508509.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127241](https://doi.org/10.1016%2Fj.ijpharm.2026.127241)
- **Detail Markdown URL:** [Directional coating of cell membranes preserves orientation and extends circulation of biomimetic](https://medichelpline.com/clinical-feed/pubmed-42508509.md)

> **Executive GIST:** - Cell membrane–coated nanocarriers aim to reduce drug toxicity and prolong systemic circulation by using natural cell membranes as a biomimetic shell. - A major unresolved problem is membrane inside-out inversion during coating, which can impair native functions such as homologous targeting and long circulation. - The authors developed a **directional coating** strategy by screening a peptide that specifically binds **phosphatidylserine (PS)** on the inner leaflet of cell membranes and attaching that peptide to the surface of drug-loaded nanoparticles to guide correct membrane orientation. - The approach was applied to engineer red blood cell membrane (**RBCm**)–coated bufalin liposomes (BF/Lip-Pep@RBC), preserving outward display of **CD47** and internalization of PS. - Compared with non-directional coating controls, BF/Lip-Pep@RBC reduced macrophage uptake by 79.76% and extended circulation half-life by 2.24-fold. - In a breast cancer model, the directional RBCm-coated BF liposomes showed potent antitumor efficacy with acceptable biosafety as reported in the source. - The strategy addresses the often-overlooked issue of membrane orientation loss and is presented as broadly applicable and scalable for designing functionally intact cell membrane–coated nanomedicines. - Keywords highlighted in the source include **Breast cancer**, **Bufalin**, **Directional coating**, **Long circulation**, and **Red blood cell membrane**.

### 12. [Lipid-Based Nanocarriers for Curcumin Delivery in Photodynamic Therapy of Skin Cancer](https://medichelpline.com/clinical-feed/pubmed-42508506.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127226](https://doi.org/10.1016%2Fj.ijpharm.2026.127226)
- **Detail Markdown URL:** [Lipid-Based Nanocarriers for Curcumin Delivery in Photodynamic Therapy of Skin Cancer](https://medichelpline.com/clinical-feed/pubmed-42508506.md)

> **Executive GIST:** - Non-melanoma skin cancer is common and photodynamic therapy (PDT) offers a noninvasive treatment option using topical **photosensitizers**. - **Curcumin**, a polyphenolic from Curcuma longa, has potential phototoxic activity but is limited by poor skin penetration and photodegradation when applied topically. - This study developed and characterized three **lipid nanoparticles (LNPs)** for curcumin delivery, using oleic acid, super refined castor oil, Phosal 50SA®, and Phosal 50PG® in PBS with 1.5% Poloxamer 407. - Measured LNP properties: mean particle sizes ~169–189 nm, low to moderate PDIs (0.133–0.226), and negative zeta potentials (~-24 to -33 mV) across formulations A1Cur, C2Cur, and H3Cur. - Encapsulation efficiencies were high: 89% (A1Cur), 84% (C2Cur), and 69% (H3Cur). - Small angle X-ray scattering (SAXS) showed only A1Cur formed a **hexagonal liquid-crystalline phase**. - In vitro skin penetration assays indicated transdermal delivery for A1Cur, C2Cur and free curcumin, while H3Cur showed greater potential for topical retention. - Reactive oxygen species (ROS) photogeneration assays confirmed photoproduction, particularly pronounced for **H3Cur**. - In vitro 24-hour cytotoxicity and phototoxicity assays on the A431 non-melanoma skin carcinoma cell line demonstrated that LNPs enhanced cytotoxic and phototoxic effects compared with free curcumin, notably for **A1Cur**. - The A1 and A1Cur liquid crystalline nanodispersions were incorporated into dissolving microneedle systems and showed acceptable insertion capability and mechanical resistance to pressure. - Overall, the LNPs improved skin penetration potential and enhanced phototoxic and cytotoxic activity in vitro compared with free curcumin, supporting their potential as drug delivery vehicles for non-melanoma skin cancer treatment. - The abstract does not report in vivo efficacy, safety beyond in vitro assays, or clinical data; such details were not provided in the source.

### 13. [QbD-optimized EGCG–rosmarinic acid cubosomal hydrogel for controlled skin delivery and antimelanom](https://medichelpline.com/clinical-feed/pubmed-42501769.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127230](https://doi.org/10.1016%2Fj.ijpharm.2026.127230)
- **Detail Markdown URL:** [QbD-optimized EGCG–rosmarinic acid cubosomal hydrogel for controlled skin delivery and antimelanom](https://medichelpline.com/clinical-feed/pubmed-42501769.md)

> **Executive GIST:** - This study developed a topical nanostructured delivery system: **cubosomes** co-encapsulating **epigallocatechin-3-gallate (EGCG)** and **rosmarinic acid (RA)** for melanoma therapy using a Quality-by-Design (**QbD**) approach. - A systematic formulation workflow included risk assessment, Taguchi screening, and Box–Behnken design (BBD) to define a robust design space and optimize formulation variables. - The optimized cubosomes measured ~134.9 nm with a polydispersity index of 0.23 and a zeta potential of -17.9 mV, indicating good colloidal characteristics. - Encapsulation efficiencies were high: EGCG 89.2% and RA 86.2%. - Cubosomes were embedded into a xanthan gum hydrogel producing a pseudoplastic topical system appropriate for dermal application. - Ex vivo skin permeation was substantially increased (EGCG ~90.5% and RA ~93.4%) and in vitro diffusion was improved (EGCG ~82.3% and RA ~86.0%). - Drug release followed a non-Fickian mechanism, consistent with combined diffusion and polymer relaxation-based release. - Enhanced cellular uptake with mitochondrial localization was observed in treated cells. - The formulation showed potent antimelanoma cytotoxicity: IC50 11.3 μg/mL for human A375 cells and 32.6 μg/mL for murine B16F10 cells, with minimal toxicity to normal human epidermal melanocytes (NHEM). - In vivo evaluation reported significant tumor growth inhibition, good dermal tolerability, and no systemic toxicity in the reported model. - Overall, the **EGCG–RA cubosomal hydrogel** is presented as a promising controlled dermal delivery platform for melanoma therapy based on formulation performance and preclinical efficacy data reported in the source.

### 14. [CD44-targeted hyaluronic acid–podophyllotoxin micelles with dual-stimuli responsiveness for lung c](https://medichelpline.com/clinical-feed/pubmed-42492642.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127214](https://doi.org/10.1016%2Fj.ijpharm.2026.127214)
- **Detail Markdown URL:** [CD44-targeted hyaluronic acid–podophyllotoxin micelles with dual-stimuli responsiveness for lung c](https://medichelpline.com/clinical-feed/pubmed-42492642.md)

> **Executive GIST:** - The study reports creation of dual-targeting, dual-cleavable prodrug micelles (HPMs) by conjugating **podophyllotoxin (PPT)** to a **hyaluronic acid (HA)** backbone via an ADH-DTDPA spacer designed to be responsive to tumor microenvironmental triggers. - The spacer (adipic dihydrazide-3,3'-dithiodipropionic acid) confers **dual-stimuli responsiveness** allowing rapid micelle disassembly under acidic pH (pH 5.0) and reducing conditions (high GSH), mimicking tumor microenvironment (TME) conditions. - In vitro, HPMs showed efficient **CD44-mediated** uptake into NCI-H1299 lung cancer cells, supporting active targeting via HA–CD44 interactions. - Microscale thermophoresis (MST) quantified binding between the HA-based micelles and CD44, reporting a dissociation constant of **KD = 15.3 μM**, providing quantitative evidence of the targeting mechanism. - In vivo studies demonstrated accumulation of HPMs at tumor sites and superior tumor growth inhibition by HPMs at 10 mg/kg compared with free PPT at 15 mg/kg. - HPMs produced tumor inhibition without inducing observable **hepatotoxicity** or **nephrotoxicity**, indicating an improved safety profile versus free PPT in the reported experiments. - The authors conclude that the HPM design offers a potentially safe delivery strategy to address PPT’s poor aqueous solubility and systemic toxicity and provide molecular-level evidence to inform rational design of targeted nanomedicines for lung cancer. - Keywords emphasized by the source include **Dual-cleavable**, **Hyaluronic acid**, **Podophyllotoxin**, and **Targeting micelles**.

### 15. [Inhaled paclitaxel nanoagglomerate delivery for lung cancer: biodistribution and efficacy in biore](https://medichelpline.com/clinical-feed/pubmed-42476273.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127213](https://doi.org/10.1016%2Fj.ijpharm.2026.127213)
- **Detail Markdown URL:** [Inhaled paclitaxel nanoagglomerate delivery for lung cancer: biodistribution and efficacy in biore](https://medichelpline.com/clinical-feed/pubmed-42476273.md)

> **Executive GIST:** - Integrating pulmonary drug delivery with nanotechnology, the study tested an inhalable **paclitaxel (PTX)** nanoagglomerate powder (PTX-NADP) as a strategy to improve lung cancer chemotherapy. - Researchers developed an in vitro air-liquid interface (**ALI**) lung cancer organoid (**LCO**) culture model intended for biorelevant screening of inhalable anticancer formulations. - Aerosolized **PTX-NADP** produced dose-dependent antitumor effects and outperformed raw PTX powder in ALI FA34-O LCO cultures, indicating superior in vitro efficacy for the inhalable nanoagglomerate formulation. - In vivo, intratracheal (IT) instillation of PTX nanosuspensions reconstituted from PTX-NADP increased pulmonary PTX concentrations and reduced off-target tissue distribution compared with intravenous (IV) injection. - In an orthotopic lung adenocarcinoma mouse model, IT administration of reconstituted PTX nanosuspensions was well tolerated and achieved numerically similar tumor growth suppression (approximately **67%**) relative to IV injection despite lower cumulative doses. - Combining IT and IV treatments led to a higher proportion of mice with reduced tumor burden, suggesting potential for therapeutic intensification by pairing inhaled and systemic chemotherapy. - The findings support the therapeutic promise of **inhaled nanoparticle-based chemotherapy** via PTX-NADP and endorse the ALI LCO platform as a novel new approach methodology (NAM) for biorelevant preclinical screening of inhalable chemotherapy formulations. - The paper declares no competing financial interests or personal relationships; further methodological details, specific quantitative biodistribution values, and exact group sizes were not reported in the abstract and would require consulting the full text for confirmation.

### 16. [Fluorinated Nanohybrid Micelles with Lutetium-177 and Gold for Potentiated Internal Radiotherapy](https://medichelpline.com/clinical-feed/pubmed-42476272.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127219](https://doi.org/10.1016%2Fj.ijpharm.2026.127219)
- **Detail Markdown URL:** [Fluorinated Nanohybrid Micelles with Lutetium-177 and Gold for Potentiated Internal Radiotherapy](https://medichelpline.com/clinical-feed/pubmed-42476272.md)

> **Executive GIST:** - The study reports development of a **micellar nanocarrier** assembled from fluorinated amphiphiles and engineered to carry three functional components: the therapeutic radionuclide **lutetium-177 (177Lu)**, **gold nanoparticles (AuNPs)** for radiosensitization, and molecular oxygen to address **tumor hypoxia**. - The platform is described as a multifunctional **nanohybrid micelle** intended for internal radiotherapy that integrates radiation emission, dose enhancement via high-Z material, and local oxygen delivery. - In vitro evaluation used B16F10 melanoma cells; micelles containing both AuNPs and [177Lu] demonstrated significantly greater **radiocytotoxicity** than micelles with [177Lu] alone, indicating a synergistic radiosensitizing effect of gold. - In vivo testing involved mice bearing subcutaneous B16F10 tumors. A single **intratumoral injection** of AuNP@[177Lu]Lu-micelles produced sustained tumor growth control in this radioresistant model. - Quantitatively, AuNP@[177Lu]Lu-micelles achieved approximately **78% inhibition of tumor growth at day 7** post-treatment in the B16F10 model. - The authors highlight the potential therapeutic value of combining **177Lu**, **gold-mediated dose enhancement**, and oxygen delivery within a single nanoplatform for improved radiotherapy outcomes. - The abstract does not report specific experimental parameters such as micelle size distribution, gold nanoparticle size or loading, activity of 177Lu, oxygen payload metrics, detailed dosing regimen, or comprehensive toxicity and biodistribution data; those details were not reported in the PubMed abstract. - Keywords listed by the authors include: Gold nanoparticles; Lutetium-177; Micelles; Nanomedicine; Radiotherapy. The authors declared no competing interests.

### 17. [Targeted Glucose Oxidase Nanotherapy for Single‑Dose Prostate Cancer Treatment](https://medichelpline.com/clinical-feed/pubmed-42442513.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127194](https://doi.org/10.1016%2Fj.ijpharm.2026.127194)
- **Detail Markdown URL:** [Targeted Glucose Oxidase Nanotherapy for Single‑Dose Prostate Cancer Treatment](https://medichelpline.com/clinical-feed/pubmed-42442513.md)

> **Executive GIST:** - The study evaluates encapsulation of **glucose oxidase (GOX)** in a poly-l-lysine–grafted–polyethylene glycol (**PLL-g-PEG**) copolymer to improve tumor-localized cytotoxicity and reduce systemic toxicity. - A monoclonal antibody against **prostate-specific membrane antigen (PSMA)** was conjugated to the nanoparticle shell to enable receptor-mediated targeting to PSMA-expressing prostate cancer cells. - The formulated nanoparticles averaged ~30 nm in diameter and had a neutral ζ-potential according to the report. - In vitro, the targeted nanoparticles exhibited greater cytotoxicity against PSMA-positive prostate cancer cells than free GOX. - In vivo, a single intratumoral dose of the targeted nanoparticles suppressed tumor growth and prolonged survival: survival increased fourfold versus untreated controls and 1.8-fold versus free GOX-treated mice. - Biocompatibility experiments showed a marked reduction in general GOX toxicity when delivered via the nanoparticles and no adverse immune response was observed in the reported assays. - Overall, the work supports encapsulation plus PSMA-directed delivery of GOX as a potentially more efficient and safer therapeutic approach for prostate cancer compared with unencapsulated enzyme administration. - The article reports animal model data; specific experimental protocols, dosing regimens, statistical details, and full methodological parameters are available only in the full text and are not reproduced in the abstract-level source.

### 18. [Isoflavone-derived mitochondrial complex I inhibitor IV-16 shows potent activity against NSCLC](https://medichelpline.com/clinical-feed/pubmed-42217500.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.110036](https://doi.org/10.1016%2Fj.bioorg.2026.110036)
- **Detail Markdown URL:** [Isoflavone-derived mitochondrial complex I inhibitor IV-16 shows potent activity against NSCLC](https://medichelpline.com/clinical-feed/pubmed-42217500.md)

> **Executive GIST:** - Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality and motivates discovery of new therapeutics targeting tumor bioenergetics. - The study designed and synthesized 27 novel **isoflavone** derivatives to optimize a prior complex I inhibitor, DBI-2. - Compound **IV-16** emerged as the most active analog, with an antiproliferative IC50 of **0.43 μM** against human NSCLC A549 cells and ~2.7-fold greater potency than DBI-2, while showing low cytotoxicity to normal cells. - IV-16 suppressed the cellular oxygen consumption rate (OCR); this inhibition was reversed by the complex II substrate succinate, supporting selective inhibition of **mitochondrial complex I**. - Molecular dynamics simulations supported a binding mode for IV-16 involving dominant interactions with residues **GLU204** and **PHE86** in complex I. - In vitro, IV-16 inhibited A549 cell migration and induced apoptosis. - IV-16 activated the **AMPK** signaling pathway and inhibited the downstream **mTOR/S6** axis, triggering autophagy. - In silico ADMET predictions indicated favorable pharmacokinetic properties and low predicted toxicity risk for IV-16. - The report presents structure-activity relationships (SAR) across the 27 isoflavone derivatives and identifies IV-16 as a promising lead for further development against NSCLC. - Details on in vivo efficacy, full experimental protocols, and comprehensive safety profiling were not reported in the abstract and would require consultation of the full text for confirmation.

### 19. [VEGFR2-targeted NIR-II fluorescent probe ICG-VTP for precise ovarian cancer imaging and surgical n](https://medichelpline.com/clinical-feed/pubmed-42184579.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.110017](https://doi.org/10.1016%2Fj.bioorg.2026.110017)
- **Detail Markdown URL:** [VEGFR2-targeted NIR-II fluorescent probe ICG-VTP for precise ovarian cancer imaging and surgical n](https://medichelpline.com/clinical-feed/pubmed-42184579.md)

> **Executive GIST:** - Molecular imaging of tumor biomarkers can improve precision diagnosis and intraoperative guidance; **VEGFR2** is a central regulator of tumor angiogenesis and an attractive imaging target. - The authors designed a novel VEGFR2-targeting peptide named VTP by combining the peptide K237 (HTMYYHHYQHHL), a flexible Ser-Ser-Ser linker, and an albumin-binding peptide (ABP, DICLPRWGCLWED) to extend circulation time. - Surface plasmon resonance (SPR) showed high affinity of VTP for **VEGFR2** with a dissociation constant (KD) of 15.4 nM. - VTP was conjugated to indocyanine green (ICG) to create the targeted fluorescent probe **ICG-VTP**, aiming to overcome ICG’s short half-life and lack of active targeting. - ABP modification conferred a longer blood half-life to the probe and promoted accumulation that correlated positively with VEGFR2 expression across multiple tumor models. - In vivo imaging in three tumor xenograft models—high VEGFR2 expression (SKOV3, ovarian), moderate (HCT116, colorectal), and low (A549, NSCLC)—demonstrated tumor-to-background ratios (TBR) at 10 h post-injection of 2.95, 2.05, and 1.42, respectively, supporting target-specific contrast. - The probe enabled intraoperative fluorescence navigation and facilitated precise tumor resection in the reported models. - Safety assessments reported no significant toxicity at the cellular or tissue levels in the study. - The authors conclude that **ICG-VTP** shows strong specificity and improved imaging contrast for VEGFR2-positive tumors and has potential for further biomedical research and clinical translation.

### 20. [WK-13-3D inhibits triple-negative breast cancer by blocking autophagic flux via AKT/mTOR inhibitio](https://medichelpline.com/clinical-feed/pubmed-42177862.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.110015](https://doi.org/10.1016%2Fj.bioorg.2026.110015)
- **Detail Markdown URL:** [WK-13-3D inhibits triple-negative breast cancer by blocking autophagic flux via AKT/mTOR inhibitio](https://medichelpline.com/clinical-feed/pubmed-42177862.md)

> **Executive GIST:** - The study evaluated the antitumor activity of the antimicrobial peptide **WK-13-3D** against triple-negative breast cancer (TNBC) using MDA-MB-231 and MDA-MB-468 cell lines and a nude mouse xenograft model. - WK-13-3D reduced TNBC cell viability and clonogenic potential in vitro and produced antitumor effects in vivo. - Mechanistically, WK-13-3D inhibited the **AKT/mTOR** signaling pathway and bound directly to **BiP** (binding immunoglobulin protein), inducing endoplasmic reticulum (ER) stress. - Treatment caused blockade of **autophagic flux**, shown by increased autophagosome accumulation (higher LC3-II/I ratio) and impaired degradation of the autophagy substrate p62. - Lysosomal acidification and hydrolytic function were reported as preserved despite autophagic flux blockade, based on LysoTracker Red and acridine orange staining. - Activation of AKT with the activator SC79 partially reversed the autophagy dysregulation induced by WK-13-3D, indicating a role for AKT/mTOR inhibition in the observed autophagy blockade. - Overexpression of **BiP** restored autophagic flux and enhanced lysosomal activity, supporting BiP as a direct target mediating ER stress and lysosome-related effects. - The authors conclude that concurrent inhibition of **AKT/mTOR** signaling and targeting of **BiP** disrupts autophagy-lysosome crosstalk to produce an enhanced antitumor response in TNBC and propose WK-13-3D as a promising lead for further preclinical investigation.

### 21. [Pyrazolo[3,4-b]pyridine chemotype as a dual FAK1/FAK2 inhibitor for triple-negative breast cancer](https://medichelpline.com/clinical-feed/pubmed-42172799.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.110005](https://doi.org/10.1016%2Fj.bioorg.2026.110005)
- **Detail Markdown URL:** [Pyrazolo[3,4-b]pyridine chemotype as a dual FAK1/FAK2 inhibitor for triple-negative breast cancer](https://medichelpline.com/clinical-feed/pubmed-42172799.md)

> **Executive GIST:** - Triple-negative breast cancer (TNBC) has limited therapeutic targets and remains difficult to treat, prompting interest in new targeted agents. - The study used virtual screening to identify a **pyrazolo[3,4-b]pyridine** scaffold as a candidate for dual inhibition of **FAK1/FAK2**. - Sixteen derivatives of the scaffold were synthesized and evaluated; compound **8a** emerged with the strongest binding to both FAK1 and FAK2. - Measured KD values for 8a were 2.9 μM (FAK1) and 2.5 μM (FAK2), indicating micromolar affinity for both kinases. - Intracellular target engagement assays showed that 8a protected specific peptides within the kinase domains of FAK1 and FAK2 inside cells, supporting on-target binding. - Functionally, 8a caused G2/M cell-cycle arrest and activated DNA damage–related signaling, with a reduction in CDK1 phosphorylation. - The antiproliferative effect of 8a was reduced when FAK1/FAK2 were knocked down, indicating target-dependence. - Combining 8a with doxorubicin produced a significantly enhanced antiproliferative effect compared with 8a alone. - In vivo, 8a inhibited growth of 4 T1 tumors without causing significant body weight loss in treated animals. - The authors conclude that the **pyrazolo[3,4-b]pyridine** scaffold is a novel chemotype for **dual FAK1/FAK2** targeting and that 8a is a target-dependent lead for anti-TNBC development. - Specific experimental details (full structure-activity relationships, dosing regimens, statistical analyses, and comprehensive safety data) were not reported in the abstract and require consultation of the full text for verification.

### 22. [Andrographolide and Berbamine Synergy in Glioblastoma: Proteomic and Metabolomic Pathway Insights](https://medichelpline.com/clinical-feed/pubmed-42172796.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.110006](https://doi.org/10.1016%2Fj.bioorg.2026.110006)
- **Detail Markdown URL:** [Andrographolide and Berbamine Synergy in Glioblastoma: Proteomic and Metabolomic Pathway Insights](https://medichelpline.com/clinical-feed/pubmed-42172796.md)

> **Executive GIST:** - Glioblastoma (GB) is an aggressive, invasive brain cancer with poor prognosis and frequent recurrence; standard therapies such as temozolomide and radiotherapy have toxicity and long-term adverse effects, motivating study of plant-derived alternatives. - This study evaluated two phytocompounds, **andrographolide** (a diterpenoid) and **berbamine** (an alkaloid), for cytotoxic and mechanistic effects against GB cell lines. - In vitro assays used human GB cell lines LN229 and U-87 MG for efficacy and HEK 293 cells to assess safety. - Cytotoxicity and functional assays included MTT viability tests and wound healing assays; apoptosis was measured by Annexin V and other flow cytometry–based assays assessed cell cycle, oxidative stress, and mitochondrial dysfunction. - The combined treatment of andrographolide plus berbamine produced greater cell death, reduced wound healing capacity, and increased oxidative stress compared with individual treatments. - In silico analyses (Swiss Target Prediction and WebGestalt) indicated potential molecular targets and implicated pathways related to **metabolism**, **cell communication**, and **biological regulation**, with relevance to apoptosis and cell-cycle control. - Proteomic and metabolomic follow-up used differential scanning calorimetry (DSC), mass spectrometry, and NMR to detect protein structural changes and metabolite alterations, showing the combination imposed significant **metabolic stress** on GB cells. - The authors conclude that simultaneous disruption of multiple cellular pathways by this phytocompound combination highlights its potential as a therapeutic approach for targeting glioblastoma; detailed numerical results and specific target identities were not reported in the abstract. - Study details: Vijeta Prakash et al., Bioorganic Chemistry, 2026; PMID 42172796; DOI 10.1016/j.bioorg.2026.110006.

### 23. [Gold(I) complexes as anticancer agents: mechanisms, design, and immune activation](https://medichelpline.com/clinical-feed/pubmed-42166960.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.109969](https://doi.org/10.1016%2Fj.bioorg.2026.109969)
- **Detail Markdown URL:** [Gold(I) complexes as anticancer agents: mechanisms, design, and immune activation](https://medichelpline.com/clinical-feed/pubmed-42166960.md)

> **Executive GIST:** - Gold(I) complexes, historically used for arthritis, have emerged as promising **anticancer** agents with a multifaceted mode of action. - FDA-approved gold drugs include **auranofin (AF)** and sodium aurothiomalate; AF is the only gold(I) compound currently in cancer clinical trials according to the source. - Ligand selection (phosphines, N-heterocyclic carbenes, thiolates, anions, alkynyls) governs complex stability, reactivity, cellular uptake, and target selectivity. - A primary biochemical target of many gold(I) complexes is **thioredoxin reductase (TrxR)** and other thiol/selenol-containing enzymes via Au–S or Au–Se coordination. - Mechanistic consequences include disruption of mitochondrial metabolism, induction of oxidative stress, and activation of apoptotic pathways, consistent with **polypharmacology**. - Recent preclinical work indicates some gold(I) complexes can modulate the immune response: inducing **immunogenic cell death (ICD)**, altering redox-sensitive cytokine signaling, and reshaping the tumor microenvironment (TME). - These immune effects provide rationale for combining gold(I) complexes with **immune checkpoint inhibitors (ICIs)** and other immunotherapies. - Structure-activity relationship (SAR) and medicinal chemistry innovations are central to improving efficacy, selectivity, and pharmacological profiles. - Despite progress, translation remains limited: AF is the only gold(I) agent progressing in cancer clinical trials; broader clinical validation and addressing current challenges are needed. - The authors propose integrating medicinal-chemistry-driven design with immuno-oncology strategies to advance clinical development of gold(I) anticancer therapeutics.

### 24. [Dual A2AR/EGFR‑targeting thiazolyl‑pyrazoline hybrids for restoring apoptosis in colorectal cancer](https://medichelpline.com/clinical-feed/pubmed-42155202.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.109985](https://doi.org/10.1016%2Fj.bioorg.2026.109985)
- **Detail Markdown URL:** [Dual A2AR/EGFR‑targeting thiazolyl‑pyrazoline hybrids for restoring apoptosis in colorectal cancer](https://medichelpline.com/clinical-feed/pubmed-42155202.md)

> **Executive GIST:** - The study developed novel **thiazolyl‑pyrazoline** hybrids designed as dual inhibitors of the **Adenosine A2A receptor (A2AR)** and **Epidermal Growth Factor Receptor (EGFR)** to address therapeutic limitations in colorectal cancer (CRC). - A molecular hybridization approach combined pharmacophores from Gefitinib and Tozadenant to create three chemical series, which underwent molecular docking and iterative biological testing. - Two lead compounds, **6aii** and **10b**, showed potent cytotoxicity against Caco2 colorectal cancer cells with IC50 values of 0.037 ± 0.10 μM and 0.6125 ± 0.13 μM, respectively. - Enzyme inhibition assays demonstrated low‑to‑submicromolar activity against EGFR and A2AR (EGFR IC50 range reported 1.53 ± 0.12 to 8.37 ± 0.03 μM; A2AR IC50 range reported 0.037 ± 0.21 to 0.6125 ± 0.15 μM). - Mechanistic studies indicated induction of S and G2/M cell cycle arrest and modulation of apoptotic gene expression: upregulation of pro‑apoptotic genes **Caspase‑3, TP53, Bax** and downregulation of the anti‑apoptotic gene **Bcl‑2**. - Compound 6ii (noted in abstract) produced the lowest intracellular cAMP levels, supporting suppression of **A2AR** downstream signaling. - In vivo validation using the azoxymethane (AOM)‑induced CRC mouse model showed restoration of colonic crypt architecture, suppression of EGFR overexpression, and acceptable liver serum enzyme safety profiles. - The authors conclude these dual‑targeting hybrids provide a preclinical framework for multi‑target drug discovery in advanced CRC. Specific experimental details (full synthetic routes, complete structure‑activity relationship tables, statistical methods, group sizes, dosing regimens) were not reported in the PubMed abstract and would require consultation of the full text.

### 25. [Mixed Aryl‑Alkyl Succinates as Modulators of Autophagy and Apoptosis in Gastric Cancer](https://medichelpline.com/clinical-feed/pubmed-42150410.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.bioorg.2026.109997](https://doi.org/10.1016%2Fj.bioorg.2026.109997)
- **Detail Markdown URL:** [Mixed Aryl‑Alkyl Succinates as Modulators of Autophagy and Apoptosis in Gastric Cancer](https://medichelpline.com/clinical-feed/pubmed-42150410.md)

> **Executive GIST:** - Researchers synthesized a series of nine **mixed aryl-alkyl succinate** esters using a previously described alkoxy-aryloxycarbonylation of alkenes methodology and tested them in gastric cancer models. - Compounds were screened for cytotoxicity against AGS and KATO III gastric carcinoma cell lines; three compounds (2d, 2a, 2c) showed the greatest activity. - Compound 2d (R = (CH2)4CH3) was the most potent, with reported IC50 values of **30.9 μM in AGS** cells and **19 μM in KATO III** cells. - Mechanistic assays indicated that 2d increased levels of activated/cleaved **Caspase-3**, enhanced **PARP** cleavage, and promoted **LC3B** lipidation, consistent with induction of apoptosis and autophagy-related processes. - Ultrastructural analysis of cells treated with 2d revealed morphological features of early and late apoptosis, including cytoplasmic vacuolization and autophagic vacuoles. - Treatment with 2d did not alter expression of apoptosis markers in healthy GES-1 gastric epithelial cells, suggesting selective activity and an initial favorable safety signal. - The study links specific structural features of succinate derivatives to antitumor activity and supports further medicinal chemistry optimization of succinate-based agents for gastric cancer. - Details such as full experimental protocols, complete dose–response curves for all compounds, in vivo data, and broader toxicity profiling were not reported in the abstract and would require consulting the full text.

### 26. [Truncated-itraconazole Analogues as Hedgehog/GLI Inhibitors for Cutaneous Squamous Cell Carcinoma](https://medichelpline.com/clinical-feed/pubmed-42085720.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ejmech.2026.118905](https://doi.org/10.1016%2Fj.ejmech.2026.118905)
- **Detail Markdown URL:** [Truncated-itraconazole Analogues as Hedgehog/GLI Inhibitors for Cutaneous Squamous Cell Carcinoma](https://medichelpline.com/clinical-feed/pubmed-42085720.md)

> **Executive GIST:** - Cutaneous squamous cell carcinoma (cSCC) is common and can be aggressive, with limited options for advanced disease. The **Hedgehog/GLI** signaling pathway is a therapeutic target in cSCC. - Itraconazole (ITZ) is a repurposed antifungal that inhibits the **HH/GLI** pathway but has unfavorable physicochemical properties that limit its use. - The authors designed truncated-ITZ analogues starting from a metabolite-inspired lead (A-26) and synthesized two series of compounds using structure-based drug design and optimization guided by **ligand-lipophilicity efficiency**. - Compound 16 emerged as a lead with potent **HH/GLI** pathway inhibition and improved aqueous solubility compared with parent scaffolds. - In vitro, compound 16 selectively inhibited proliferation of A431 squamous cell carcinoma cells, reduced colony formation, and induced apoptosis. - In an A431 xenograft model, compound 16 significantly suppressed tumor growth and downregulated tumor markers GLI1, Ki67, and SOX2. - Preliminary safety assessment reported no significant hematological or organ toxicity in the tested model. - The study supports further development of truncated-ITZ analogues, especially compound 16, as potential therapeutic agents targeting **Hedgehog/GLI** signaling in cSCC.

### 27. [FDA Grants Accelerated Approval to Etcamah for ESR1-Mutant HR+/HER2− Advanced Breast Cancer](https://medichelpline.com/clinical-feed/fda-news-releases-1-fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment.md)
- **Source:** FDA News Releases | **Published:** 2026-09-04
- **Detail Markdown URL:** [FDA Grants Accelerated Approval to Etcamah for ESR1-Mutant HR+/HER2− Advanced Breast Cancer](https://medichelpline.com/clinical-feed/fda-news-releases-1-fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment.md)

> **Executive GIST:** - The FDA granted **accelerated approval** to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adults with hormone receptor–positive, HER2‑negative locally advanced or metastatic breast cancer when an **ESR1** resistance mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy, using an FDA‑authorized test. - The approval is contingent on confirmatory trials because the approval was based on a surrogate/intermediate endpoint rather than a demonstrated long‑term clinical benefit. - The decision represents the first FDA approval of a cancer therapy guided by detection of a resistance mutation in circulating tumor DNA (**ctDNA**) before radiographic progression is evident. - Efficacy was evaluated in a trial comparing switching to Etcamah plus a CDK4/6 inhibitor versus continuing an aromatase inhibitor plus a CDK4/6 inhibitor; estimated median **progression‑free survival** was 16 months for the Etcamah arm and 9.2 months for the aromatase inhibitor arm. - The FDA authorized the Guardant360 CDx assay as the companion diagnostic to identify patients with **ESR1** mutations for Etcamah treatment. - The prescribing information includes a boxed warning for risk of irregular heart rhythm when Etcamah is coadministered with certain drugs, plus warnings for bradycardia and potential fetal harm. - The accelerated approval was granted to AstraZeneca following review and an Oncologic Drugs Advisory Committee meeting on April 30, 2026; full prescribing information will be posted on Drugs@FDA. - At initial diagnosis of HR‑positive metastatic breast cancer, fewer than 5% of patients have an **ESR1** mutation; after progression on aromatase inhibitors, nearly 40% will have acquired this mutation, underscoring its role in acquired endocrine resistance. - The FDA based the accelerated approval on measurement of the time patients lived without disease worsening from the point the resistance mutation was first detected in blood; the agency required confirmatory studies to verify clinical benefit.

### 28. [Mass General Brigham drops Dana‑Farber from Medicare Advantage network, affecting cancer patients](https://medichelpline.com/clinical-feed/stat-news-0-stat-top-boston-hospitals-clash-over-medicare-advantage-network-after-split.md)
- **Source:** STAT News | **Published:** 2026-09-04
- **Detail Markdown URL:** [Mass General Brigham drops Dana‑Farber from Medicare Advantage network, affecting cancer patients](https://medichelpline.com/clinical-feed/stat-news-0-stat-top-boston-hospitals-clash-over-medicare-advantage-network-after-split.md)

> **Executive GIST:** - Mass General Brigham’s Medicare Advantage plan is removing **Dana‑Farber** Cancer Institute from its provider network effective Oct. 1, 2026, forcing some members to choose between changing oncologists or changing plans. - The Medicare Advantage plan, operated by Mass General Brigham’s insurance arm, covers roughly **20,500** members; only a subset of those receive cancer care at Dana‑Farber at any given time. - The article opens with a patient example: 88‑year‑old Eldon Clingan, who has been treated by the same Dana‑Farber oncologist for decades and says he may need to switch physicians or insurance after the network change. - The story is published as a STAT+ exclusive and was written by Marin Wolf for the Boston Globe on Sept. 4, 2026; full article content beyond the lead was behind the STAT+ paywall. - The source reports the core facts above but does not publish additional contractual details, the reasons for the network change, responses from the institutions involved, precise counts of affected cancer patients, or information on appeals or transition policies; those details were not reported in the source. - The available coverage situates the dispute at the intersection of **health insurance networks**, hospital systems’ insurance arms, and patient access to specialty cancer care, but specific negotiations, clinical continuity plans, or patient protections were not detailed in the source. - The article is categorized under cancer, health insurance, hospitals, Medicare Advantage, and patients; it is labeled STAT+ exclusive content requiring subscription to view the full report.

### 29. [Natural products targeting HBx in HBV-related hepatocellular carcinoma: mechanisms and potential](https://medichelpline.com/clinical-feed/pubmed-42693910.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1080/13880209.2026.2724161](https://doi.org/10.1080%2F13880209.2026.2724161)
- **Detail Markdown URL:** [Natural products targeting HBx in HBV-related hepatocellular carcinoma: mechanisms and potential](https://medichelpline.com/clinical-feed/pubmed-42693910.md)

> **Executive GIST:** - Hepatocellular carcinoma (HCC) is frequently driven by chronic **HBV** infection; the viral X protein (**HBx**) is a multifunctional oncoprotein central to HBV persistence and hepatocarcinogenesis. - **HBx** disrupts transcriptional regulation, DNA repair, apoptosis, and immune responses, and thereby promotes malignant transformation and tumor progression. - This review surveyed the past decade of literature, including **in vitro**, **in vivo**, and clinical evidence, assessing natural products that directly or indirectly target **HBx** or **HBx**-associated pathways. - Some natural compounds suppress HBV replication by reducing **HBx** expression, enhancing **HBx** degradation, or limiting **HBx**-dependent **cccDNA** transcriptional activity. - Other bioactive natural products modulate downstream oncogenic processes linked to **HBx**, such as cell migration, invasion, liver fibrosis, metabolic reprogramming, and resistance to apoptosis. - The reviewed agents include plant-derived phytochemicals and non-plant natural compounds; specific compound names and doses were not provided in the abstract. - Evidence supporting activity comes from preclinical models and limited clinical data reported in the literature; the abstract does not list trial outcomes or detailed study metrics. - Authors conclude that **natural products** offer a promising multi-target therapeutic strategy for HBV-related HCC by intervening in **HBx**-driven oncogenic processes. - Key translational gaps identified include the need for mechanistic validation, standardization of bioactive compounds, and well-designed clinical trials to enable clinical application. - Overall, the review frames **HBx-targeted natural products** as potential adjunctive or alternative therapies for HBV-related HCC, while noting that further rigorous research is required.

### 30. [Global spatiotemporal co-burden and population risk factors for esophageal and lip/oral cavity can](https://medichelpline.com/clinical-feed/pubmed-42693829.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1080/07853890.2026.2721134](https://doi.org/10.1080%2F07853890.2026.2721134)
- **Detail Markdown URL:** [Global spatiotemporal co-burden and population risk factors for esophageal and lip/oral cavity can](https://medichelpline.com/clinical-feed/pubmed-42693829.md)

> **Executive GIST:** - This machine learning-driven systematic analysis used Global Burden of Disease 2021 data to examine country-level co-burden of **esophageal cancer** and **lip and oral cavity (LOC) cancer** in adults aged ≥55 across 203 countries and territories. - Incidence rates were categorized into quartile-based co-burden groups and compared over 1990–2021 alongside Socio-demographic Index (SDI) trajectories to identify temporal trends. - The study screened 58 candidate population-level exposures. Random forests with SHapley Additive exPlanations (SHAP) reduced features to 36, then variance inflation factor screening narrowed to 25 variables for multivariable negative binomial models with population offsets. - Countries were classified into three co-burden patterns: consistent co-burden (n=73), **esophageal cancer**-dominant (n=61), and **LOC**-dominant (n=69). - Higher SDI generally corresponded with declining **esophageal cancer** incidence, while **LOC** incidence increased in several high-SDI settings. - Both cancers showed ecological positive associations with high **alcohol use** and diets low in **nuts and seeds** (reported rate ratios and 95% CIs provided in the source abstract). - Additional ecological associations: **esophageal cancer** with iron deficiency, occupational exposure to particulate matter/gases/fumes, and high red meat diets; **LOC** with **chewing tobacco** use and high-sodium diets. - Reported associations are ecological and do not establish individual-level causality; findings are intended to inform regionally tailored prevention priorities. - The source reports effect estimates (rate ratios with 95% CIs) for identified associations; other methodological specifics beyond the abstract were not reported in the provided source text.

## Machine-Readable Pagination & Traversal
- [← Main Clinical Feed Hub](https://medichelpline.com/clinical-feed.md)
- [Next Page (Page 2) →](https://medichelpline.com/clinical-feed/oncology.md?page=2)
## Other Clinical Specialties
- [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- [Dentistry](https://medichelpline.com/clinical-feed/dentistry.md)
- [Public Health](https://medichelpline.com/clinical-feed/public-health.md)
- [Regulatory & FDA](https://medichelpline.com/clinical-feed/regulatory.md)
- [Research & Trials](https://medichelpline.com/clinical-feed/research.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.